Effects of ICL670 (deferasirox) on cardiac iron concentrations
- 9 September 2005
- journal article
- other
- Published by Elsevier in The Lancet
- Vol. 366 (9488) , 804
- https://doi.org/10.1016/s0140-6736(05)67205-4
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Phase III Evaluation of Once-Daily, Oral Therapy with ICL670 (Exjade®) Versus Deferoxamine in Patients with β-Thalassemia and Transfusional Hemosiderosis.Blood, 2004
- Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonanceBritish Journal of Haematology, 2004
- Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemiaBritish Journal of Haematology, 2004
- Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trialThe Lancet, 2003
- ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in cultureBlood, 2001